Lord, Abbett & Co. LLC Ventyx Biosciences, Inc. Transaction History

Lord, Abbett & Co. LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 07, 2024	SELL	$29.8 - $40.3 $17.5 Million - $23.7 Million	-587,711 Reduced 25.36%	1,729,464 $60.1 Million
Q3 2023 Nov 13, 2023	SELL	$29.8 - $40.3 $17.5 Million - $23.7 Million	-587,711 Reduced 25.36%	1,729,464 $60.1 Million
Q2 2023 Oct 07, 2024	BUY	$28.53 - $39.55 $28.5 Million - $39.5 Million	998,782 Added 75.76%	2,317,175 $76 Million
Q2 2023 Aug 14, 2023	BUY	$28.53 - $39.55 $28.5 Million - $39.5 Million	998,782 Added 75.76%	2,317,175 $76 Million
Q1 2023 Oct 07, 2024	SELL	$29.51 - $46.65 $15.5 Million - $24.5 Million	-525,014 Reduced 28.48%	1,318,393 $44.2 Million
Q1 2023 May 12, 2023	SELL	$29.51 - $46.65 $15.5 Million - $24.5 Million	-525,014 Reduced 28.48%	1,318,393 $44.2 Million
Q4 2022 Oct 07, 2024	BUY	$24.16 - $36.38 $44.5 Million - $67.1 Million	1,843,407 New	1,843,407 $60.4 Million
Q4 2022 Feb 10, 2023	BUY	$24.16 - $36.38 $2.55 Million - $3.84 Million	105,629 Added 6.08%	1,843,407 $60.4 Million
Q3 2022 Nov 14, 2022	BUY	$12.64 - $38.7 $22 Million - $67.3 Million	1,737,778 New	1,737,778 $60.7 Million

125

52.9M

35.3K

83K

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $128M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.